Recruiting Clinical Trials

A Study of LY3023414 in Participants With Advanced Cancer

By April 24, 2017 No Comments


Advanced Cancer|Metastatic Cancer|Non-Hodgkin’s Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer

Estimated Enrollment: 130

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 13517|I6A-MC-CBBA

Study First Received: July 19, 2012

Last Updated: March 22, 2017

Estimated Primary Completion Date: March 4, 2018


Primary Outcome Measures:

Recommended Phase 2 dose|Pharmacokinetics: Maximum concentration (Cmax)|Pharmacokinetics: Time of maximal concentration|Number of participants with tumor response|Potential of LY3023414 to inhibit CYP3A4-mediated metabolism

Sponsors and Collaborators:

Eli Lilly and Company

Website Link:

Leave a Reply

Call Now